Trial · NCT02120352
Adverse events1,680
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,680
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Injection site pain | General disorders | CAB 30 mg+ABC/3TC QD (Induction Period) | 0 | 309 | 0 |
| other | Injection site pain | General disorders | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | 111 | 115 | 2,749 |
| other | Injection site pain | General disorders | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | 114 | 115 | 3,533 |
| other | Injection site pain | General disorders | CAB 30 mg+ABC/3TC QD | 0 | 56 | 0 |
| other | Injection site pain | General disorders | Optimized CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Extension Period) | 31 | 34 | 486 |
| other | Injection site pain | General disorders | Optimized CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Extension Period) | 8 | 10 | 197 |
| other | Injection site pain | General disorders | Long-Term Follow-Up Group | 4 | 43 | 4 |
| other | Injection site swelling | General disorders | CAB 30 mg+ABC/3TC QD (Induction Period) | 0 | 309 | 0 |
| other | Injection site swelling | General disorders | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | 41 | 115 | 209 |
| other | Injection site swelling | General disorders | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | 43 | 115 | 293 |
| other | Injection site swelling | General disorders | CAB 30 mg+ABC/3TC QD | 0 | 56 | 0 |
| other | Injection site swelling | General disorders | Optimized CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Extension Period) | 6 | 34 | 9 |
| other | Injection site swelling | General disorders | Optimized CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Extension Period) | 3 | 10 | 3 |
| other | Injection site swelling | General disorders | Long-Term Follow-Up Group | 0 | 43 | 0 |
| other | Injection site nodule | General disorders | CAB 30 mg+ABC/3TC QD (Induction Period) | 0 | 309 | 0 |
| other | Injection site nodule | General disorders | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | 46 | 115 | 327 |
| other | Injection site nodule | General disorders | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | 57 | 115 | 675 |
| other | Injection site nodule | General disorders | CAB 30 mg+ABC/3TC QD | 0 | 56 | 0 |
| other | Injection site nodule | General disorders | Optimized CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Extension Period) | 12 | 34 | 34 |
| other | Injection site nodule | General disorders | Optimized CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Extension Period) | 5 | 10 | 14 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02120352/events